Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology

纤维化 医学 内科学 脂肪性肝炎 胃肠病学 肝病学 病理 脂肪肝 疾病
作者
Vlad Ratziu,Yusuf Yılmaz,Don Lazas,Scott L. Friedman,C. Lackner,Cynthia Behling,Oscar W. Cummings,Li Chen,Mathieu Petitjean,Yossi Gilgun‐Sherki,Tali Gorfine,Shaul Kadosh,Eli Eyal,Arun J. Sanyal
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
被引量:5
标识
DOI:10.1097/hep.0000000000000980
摘要

Background and Aims: Antifibrotic trials rely on conventional pathology despite recognized limitations. We compared single-fiber digital image analysis with conventional pathology to quantify the antifibrotic effect of Aramchol, a stearoyl-CoA desaturase 1 inhibitor in development for metabolic dysfunction–associated steatohepatitis. Approach and Results: Fifty-one patients with metabolic dysfunction–associated steatohepatitis enrolled in the open-label part of the ARMOR trial received Aramchol 300 mg BID and had paired pre-post treatment liver biopsies scored by consensus among 3 hepatopathologists, and separately assessed by a digital image analysis platform (PharmaNest) that generates a continuous phenotypic Fibrosis Composite Severity (Ph-FCS) score. Fibrosis improvement was defined as: ≥1 NASH Clinical Research Network (NASH-CRN) stage reduction; “improved” by ranked pair assessment; reduction in Ph-FCS (“any” for ≥0.3 absolute reduction and “substantial” for ≥25% relative reduction). Fibrosis improved in 31% of patients (NASH-CRN), 51% (ranked pair assessment), 74.5% (any Ph-FCS reduction), and 41% (substantial Ph-FCS reduction). Most patients with stable fibrosis by NASH-CRN or ranked pair assessment had a Ph-FCS reduction (a third with substantial reduction). Fibrosis improvement increased with treatment duration: 25% for <48 weeks versus 39% for ≥48 weeks by NASH-CRN; 43% versus 61% by ranked pair assessment, mean Ph-FCS reduction −0.54 (SD: 1.22) versus −1.72 (SD: 1.02); Ph-FCS reduction (any in 54% vs. 100%, substantial in 21% vs. 65%). The antifibrotic effect of Aramchol was corroborated by reductions in liver stiffness, Pro-C3, and enhanced liver fibrosis. Changes in Ph-FCS were positively correlated with changes in liver stiffness. Conclusions: Continuous fibrosis scores generated in antifibrotic trials by digital image analysis quantify antifibrotic effects with greater sensitivity and a larger dynamic range than conventional pathology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
暖暖完成签到,获得积分10
刚刚
1秒前
18621058639完成签到,获得积分10
1秒前
pbj发布了新的文献求助10
2秒前
额我认为发布了新的文献求助10
2秒前
M27发布了新的文献求助10
2秒前
在水一方应助vvvaee采纳,获得10
3秒前
djf点儿完成签到 ,获得积分10
4秒前
5秒前
Hhl完成签到,获得积分10
6秒前
6秒前
爆米花应助好运采纳,获得10
7秒前
Lucas应助pbj采纳,获得10
7秒前
redchocobo发布了新的文献求助10
7秒前
通辽小判官完成签到,获得积分10
8秒前
newgeno2003发布了新的文献求助10
8秒前
8秒前
大个应助科研通管家采纳,获得10
8秒前
隐形曼青应助科研通管家采纳,获得10
9秒前
怡然的芯发布了新的文献求助10
9秒前
赘婿应助科研通管家采纳,获得10
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
7275XXX完成签到,获得积分10
9秒前
sujustin333发布了新的文献求助10
10秒前
清梦完成签到,获得积分10
10秒前
12秒前
NexusExplorer应助沟通亿心采纳,获得10
12秒前
顾矜应助123321采纳,获得10
12秒前
细心觅风完成签到,获得积分10
14秒前
铅笔995发布了新的文献求助20
14秒前
大个应助ryd采纳,获得10
14秒前
15秒前
Yi羿完成签到 ,获得积分10
16秒前
16秒前
18秒前
19秒前
xinlei2023完成签到,获得积分10
20秒前
耿大海发布了新的文献求助10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970008
求助须知:如何正确求助?哪些是违规求助? 3514711
关于积分的说明 11175563
捐赠科研通 3250077
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804931